WILMINGTON, N.C.--(BUSINESS WIRE)--Optimal Research, a service of PPD’s Accelerated Enrollment Solutions (AES) business unit, was named the top clinical trial network at the 12th annual Vaccine Industry Excellence (ViE) Awards during the 2019 World Vaccine Congress in Washington, D.C.
The ViE awards celebrate the outstanding achievements of organizations and individuals setting high standards of excellence and advocacy in the vaccine industry.
Optimal’s Vaccine Centers of Excellence is the world’s largest vaccine site network, accentuated by accelerated patient enrollment services, advanced lab capabilities including peripheral blood mononuclear cells (PBMC) processing, and specialized vaccine services – all delivered under a results-based contracting model that offers cost and time certainty in trial delivery.
“This recognition by industry peers reflects our Vaccine Centers of Excellence’s success in supporting multiple and diverse clinical phase and outcomes trials,” said Krystyna Kowalczyk, chief operating officer for Optimal Oncology and Vaccines Services. “This award acknowledges our team’s expertise in helping clients quickly enroll patients and maintain extremely high retention rates.”
Examples of Optimal’s delivery success for clients include recently registering more than 350 subjects in nine business days for a research study for respiratory syncytial virus (RSV) that included specialized lab processing for each randomized patient, all while maintaining a 97 percent subject retention rate across all research study populations. Overall, Optimal has recruited more than 70,000 patients for more than 850 vaccine trials.
Accelerated Enrollment Solutions is a business unit of Pharmaceutical Product Development, LLC (PPD) that offers clients and contract research organizations best-in-class site and enrollment solutions through its service brands Synexus, Acurian and Optimal, as well as in combination with PPD’s industry-leading global clinical development services. These solutions are available as discrete services or integrated to provide a cohesive and highly differentiated trial acceleration strategy for insourced or outsourced clinical studies, all under performance-based commercial terms. For more information, visit www.globalAES.com.